XML 53 R29.htm IDEA: XBRL DOCUMENT v3.21.2

Segments of Business and Geographic Areas (Tables)

3 Months Ended

6 Months Ended

Jul. 04, 2021

Jul. 04, 2021

Segment Reporting [Abstract]

Sales By Segment Of Business

SALES BY SEGMENT OF BUSINESS

						Fiscal Second Quarter Ended																		Fiscal Six Months Ended
(Dollars in Millions)						July 4, 2021						June 28, 2020						Percent Change						July 4, 2021						June 28, 2020						Percent Change
Consumer Health
OTC
U.S.						$	675					627						7.7		%				$	1,274					1,316						(3.2)		%
International						633						522						21.2						1,208						1,181						2.3
Worldwide						1,307						1,149						13.8						2,482						2,497						(0.6)
Skin Health/Beauty
U.S.						659						536						23.0						1,293						1,195						8.2
International						511						471						8.4						1,040						929						12.0
Worldwide						1,170						1,007						16.2						2,333						2,124						9.8
Oral Care
U.S.						165						170						(3.1)						328						346						(5.2)
International						260						227						14.6						514						446						15.3
Worldwide						426						397						7.0						843						792						6.3
Baby Care
U.S.						97						96						0.8						193						188						2.4
International						290						260						11.5						583						529						10.2
Worldwide						387						356						8.6						776						717						8.1
Women's Health
U.S.						3						3						(3.1)						6						7						(16.0)
International						227						199						14.2						446						427						4.5
Worldwide						230						202						13.9						452						434						4.2
Wound Care/Other
U.S.						153						126						20.9						268						245						9.3
International						64						59						7.3						125						111						12.1
Worldwide						216						185						16.6						393						356						10.2
TOTAL Consumer Health
U.S.						1,751						1,557						12.4						3,362						3,297						2.0
International						1,984						1,739						14.1						3,916						3,624						8.1
Worldwide						3,735						3,296						13.3						7,278						6,921						5.2

PHARMACEUTICAL
Immunology
U.S.						2,748						2,362						16.4						5,161						4,772						8.2
International						1,483						1,161						27.7						2,984						2,389						24.9
Worldwide						4,231						3,523						20.1						8,145						7,161						13.7
REMICADE®
U.S.						540						593						(9.1)						1,029						1,218						(15.6)
U.S. Exports						93						133						(30.0)						150						243						(38.2)
International						255						208						22.4						487						464						4.9
Worldwide						888						935						(5.1)						1,665						1,925						(13.5)
SIMPONI / SIMPONI ARIA®
U.S.						290						256						12.8						545						528						3.2
International						294						289						1.7						601						547						9.8
Worldwide						584						546						6.9						1,146						1,075						6.6
STELARA®
U.S.						1,496						1,138						31.4						2,827						2,355						20.0
International						778						558						39.2						1,595						1,161						37.3
Worldwide						2,274						1,697						34.0						4,422						3,516						25.8
TREMFYA®
U.S.						325						241						35.0						599						428						40.0
International						155						101						52.3						298						210						41.8
Worldwide						479						342						40.2						897						638						40.6
OTHER IMMUNOLOGY
U.S.						5						—						*						12						—						*
International						1						3						(61.3)						3						6						(51.2)
Worldwide						7						3						*						15						6						*
Infectious Diseases
U.S.						444						416						6.8						956						852						12.2
International						585						463						26.3						1,079						946						14.1
Worldwide						1,028						878						17.1						2,035						1,798						13.2
COVID-19 vaccine
U.S.						51						—						*						151						—						*
International						113						—						*						113						—						*
Worldwide						164						—						*						264						—						*
EDURANT® / rilpivirine
U.S.						9						10						(9.3)						19						22						(10.9)
International						253						246						2.8						486						458						6.0
Worldwide						262						256						2.3						505						480						5.2
PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA®
U.S.						368						379						(3.2)						748						775						(3.5)
International						137						130						5.5						303						314						(3.5)
Worldwide						505						510						(1.0)						1,051						1,089						(3.5)

OTHER INFECTIOUS DISEASES
U.S.						16						25						(36.2)						37						54						(31.3)
International						81						87						(6.2)						177						174						1.8
Worldwide						98						113						(13.0)						215						229						(6.1)
Neuroscience
U.S.						842						778						8.0						1,613						1,526						5.6
International						967						809						19.6						1,916						1,719						11.5
Worldwide						1,808						1,587						13.9						3,529						3,245						8.7
CONCERTA® / methylphenidate
U.S.						35						55						(36.0)						82						107						(23.1)
International						127						94						33.7						250						212						17.5
Worldwide						161						149						8.1						332						320						3.9
INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA®
U.S.						645						576						11.9						1,234						1,120						10.2
International						380						303						25.1						756						642						17.7
Worldwide						1,024						879						16.4						1,989						1,762						12.9
RISPERDAL CONSTA®
U.S.						72						74						(3.0)						139						150						(7.5)
International						84						79						6.4						173						173						0.4
Worldwide						155						153						1.9						312						323						(3.3)
OTHER NEUROSCIENCE
U.S.						91						75						20.9						158						150						5.6
International						377						331						13.8						738						691						6.7
Worldwide						468						406						15.1						896						841						6.5
Oncology
U.S.						1,462						1,181						23.7						2,839						2,356						20.5
International						2,073						1,609						28.8						4,266						3,448						23.7
Worldwide						3,535						2,791						26.7						7,105						5,804						22.4
DARZALEX®
U.S.						770						492						56.7						1,461						955						53.1
International						663						409						62.1						1,337						883						51.4
Worldwide						1,433						901						59.2						2,798						1,838						52.2
ERLEADA®
U.S.						193						136						41.5						364						255						42.7
International						109						33						*						199						57						*
Worldwide						302						170						77.6						563						313						80.0
IMBRUVICA®
U.S.						454						447						1.7						898						879						2.2
International						662						502						31.9						1,342						1,101						21.9
Worldwide						1,116						949						17.7						2,241						1,980						13.2
ZYTIGA® / abiraterone acetate
U.S.						21						87						(75.3)						71						226						(68.5)
International						542						480						12.8						1,130						1,032						9.5
Worldwide						563						568						(0.8)						1,201						1,258						(4.5)

OTHER ONCOLOGY(1)
U.S.						23						20						18.8						44						42						6.3
International						97						185						(47.2)						258						375						(31.0)
Worldwide						120						204						(40.9)						302						416						(27.3)
Pulmonary Hypertension
U.S.						595						545						9.0						1,168						1,031						13.2
International						275						243						13.5						563						503						12.1
Worldwide						870						789						10.4						1,731						1,534						12.9
OPSUMIT®
U.S.						290						256						13.6						562						485						15.9
International						172						150						14.9						351						310						13.1
Worldwide						463						406						14.1						913						795						14.8
UPTRAVI®
U.S.						268						254						6.0						527						466						13.3
International						45						28						54.9						91						66						36.8
Worldwide						313						282						11.0						618						532						16.2
OTHER PULMONARY HYPERTENSION
U.S.						36						37						(2.4)						78						81						(3.0)
International						59						64						(8.2)						122						126						(3.5)
Worldwide						95						101						(6.1)						200						207						(3.3)
Cardiovascular / Metabolism / Other
U.S.						780						837						(6.9)						1,579						1,643						(3.9)
International						346						347						(0.3)						674						701						(3.8)
Worldwide						1,126						1,184						(5.0)						2,253						2,344						(3.9)
XARELTO®
U.S.						569						559						1.8						1,158						1,086						6.6
International						—						—						—						—						—						—
Worldwide						569						559						1.8						1,158						1,086						6.6
INVOKANA® / INVOKAMET®
U.S.						96						132						(27.0)						183						249						(26.6)
International						64						47						33.8						127						105						20.3
Worldwide						160						179						(10.9)						310						354						(12.6)
PROCRIT® / EPREX®
U.S.						59						70						(16.3)						121						146						(17.3)
International						69						66						3.7						133						145						(8.2)
Worldwide						127						136						(6.6)						254						291						(12.8)
OTHER
U.S.						57						78						(26.7)						117						163						(27.8)
International						214						234						(8.4)						415						451						(8.1)
Worldwide						271						312						(13.0)						532						614						(13.3)
TOTAL PHARMACEUTICAL
U.S.						6,869						6,120						12.2						13,315						12,181						9.3
International						5,730						4,632						23.7						11,483						9,705						18.3
Worldwide						12,599						10,752						17.2						24,798						21,886						13.3

MEDICAL DEVICES
Interventional Solutions
U.S.						475						255						86.5						909						620						46.7
International						572						335						70.5						1,086						697						55.7
Worldwide						1,046						590						77.4						1,995						1,317						51.5
Orthopaedics
U.S.						1,323						869						52.3						2,572						2,119						21.4
International						904						583						55.1						1,768						1,371						29.0
Worldwide						2,227						1,451						53.4						4,340						3,489						24.4
HIPS
U.S.						234						137						70.5						444						343						29.6
International						159						88						78.6						305						220						38.3
Worldwide						392						226						73.7						749						563						33.0
KNEES
U.S.						210						108						94.3						395						322						22.7
International						140						66						*						272						196						39.2
Worldwide						350						174						*						667						517						28.9
TRAUMA
U.S.						447						354						26.0						897						761						17.8
International						263						198						32.7						545						445						22.5
Worldwide						710						553						28.4						1,443						1,207						19.6
SPINE, SPORTS & OTHER
U.S.						433						270						60.6						836						693						20.7
International						343						230						49.0						646						510						26.7
Worldwide						776						499						55.3						1,482						1,202						23.2
Surgery
U.S.						1,035						490						*						1,933						1,334						44.9
International						1,487						1,060						40.2						2,961						2,317						27.8
Worldwide						2,522						1,551						62.6						4,894						3,651						34.0
ADVANCED
U.S.						459						277						65.4						864						658						31.3
International						708						498						42.2						1,421						1,065						33.4
Worldwide						1,168						775						50.5						2,286						1,723						32.6
GENERAL
U.S.						576						213						*						1,069						676						58.1
International						779						562						38.5						1,540						1,252						23.0
Worldwide						1,354						775						74.7						2,608						1,928						35.3
Vision
U.S.						467						248						88.3						939						687						36.6
International						716						447						60.0						1,389						1,075						29.2
Worldwide						1,183						695						70.1						2,328						1,762						32.1
CONTACT LENSES / OTHER
U.S.						352						203						73.3						723						549						31.6
International						517						352						47.0						1,003						819						22.5
Worldwide						868						554						56.7						1,725						1,368						26.1

SURGICAL
U.S.						115						45						*						216						138						56.3
International						199						96						*						386						256						50.9
Worldwide						314						141						*						602						394						52.8
TOTAL MEDICAL DEVICES
U.S.						3,299						1,862						77.2						6,353						4,760						33.5
International						3,679						2,426						51.6						7,204						5,460						31.9
Worldwide						6,978						4,288						62.7						13,557						10,220						32.7
WORLDWIDE
U.S.						11,919						9,539						24.9						23,030						20,238						13.8
International						11,393						8,797						29.5						22,603						18,789						20.3
Worldwide						$	23,312					18,336						27.1		%				$	45,633					39,027						16.9		%

*Percentage greater than 100% or not meaningful

(1) Inclusive of VELCADE® which was previously disclosed separately

Operating Profit by Segment of Business

EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT

						Fiscal Second Quarter Ended																		Fiscal Six Months Ended
(Dollars in Millions)						July 4, 2021						June 28, 2020						Percent Change						July 4, 2021						June 28, 2020						Percent Change
Consumer Health (1)						$	804					32						*						$	1,592					802						98.5%
Pharmaceutical(2)						4,356						4,514						(3.5)						9,579						8,348						14.7
Medical Devices(3)						1,746						(354)						*						3,375						1,671						*
Segment earnings before provision for taxes						6,906						4,192						64.7						14,546						10,821						34.4
Less: Expense not allocated to segments (4)						244						252												455						372
Worldwide income before tax						$	6,662					3,940						69.1%						$	14,091					10,449						34.9%

*Percentage greater than 100% or not meaningful

(1) Consumer Health

•Includes intangible amortization expense of $0.1 billion in both the fiscal second quarter of 2021 and 2020 and $0.2 billion in both the fiscal six months of 2021 and 2020.

•Includes litigation expense of $0.1 billion and $0.6 billion in both the fiscal second quarter and fiscal six months of 2021 and 2020, primarily talc related costs, respectively.

(2) Pharmaceutical

•Includes divestiture gains of $0.6 billion in the fiscal six months of 2021 related to two brands outside the U.S.

•Includes an unrealized gain on securities of $0.2 billion and $0.5 billion in the fiscal second quarter and $0.1 billion and $0.2 billion in the fiscal six months of 2021 and 2020, respectively.

•Includes intangible amortization expense of $0.8 billion in both the fiscal second quarter of 2021 and 2020. Includes intangible amortization expense of $1.7 billion and $1.6 billion in the fiscal six months of 2021 and 2020.

In fiscal 2020 and 2021, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid and contractually obligated to be paid to these contract manufacturing organizations of approximately $1.3 billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations.

(3) Medical Devices

•Includes a contingent consideration reversal of $1.0 billion in the fiscal second quarter of 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition.

•Includes a restructuring related charge of $0.1 billion in both the fiscal second quarter of 2021 and 2020, respectively.

•Includes intangible amortization expense of $0.3 billion and $0.2 billion in the fiscal second quarter and $0.5 billion in both the fiscal six months of 2021 and 2020, respectively.

•Includes an unrealized gain on securities of $0.1 billion in both the fiscal second quarter and the fiscal six months of 2021.

(4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.

EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT

						Fiscal Second Quarter Ended																		Fiscal Six Months Ended
(Dollars in Millions)						July 4, 2021						June 28, 2020						Percent Change						July 4, 2021						June 28, 2020						Percent Change
Consumer Health (1)						$	804					32						*						$	1,592					802						98.5%
Pharmaceutical(2)						4,356						4,514						(3.5)						9,579						8,348						14.7
Medical Devices(3)						1,746						(354)						*						3,375						1,671						*
Segment earnings before provision for taxes						6,906						4,192						64.7						14,546						10,821						34.4
Less: Expense not allocated to segments (4)						244						252												455						372
Worldwide income before tax						$	6,662					3,940						69.1%						$	14,091					10,449						34.9%

*Percentage greater than 100% or not meaningful

(1) Consumer Health

•Includes intangible amortization expense of $0.1 billion in both the fiscal second quarter of 2021 and 2020 and $0.2 billion in both the fiscal six months of 2021 and 2020.

•Includes litigation expense of $0.1 billion and $0.6 billion in both the fiscal second quarter and fiscal six months of 2021 and 2020, primarily talc related costs, respectively.

(2) Pharmaceutical

•Includes divestiture gains of $0.6 billion in the fiscal six months of 2021 related to two brands outside the U.S.

•Includes an unrealized gain on securities of $0.2 billion and $0.5 billion in the fiscal second quarter and $0.1 billion and $0.2 billion in the fiscal six months of 2021 and 2020, respectively.

•Includes intangible amortization expense of $0.8 billion in both the fiscal second quarter of 2021 and 2020. Includes intangible amortization expense of $1.7 billion and $1.6 billion in the fiscal six months of 2021 and 2020.

In fiscal 2020 and 2021, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provide the Company with future supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. Amounts paid and contractually obligated to be paid to these contract manufacturing organizations of approximately $1.3 billion are reflected in the prepaid expenses and other, other assets, accrued liabilities and other liabilities accounts in the Company's consolidated balance sheet upon execution of each agreement. Additionally, the Company has entered into certain vaccine development cost sharing arrangements with government related organizations.

(3) Medical Devices

•Includes a contingent consideration reversal of $1.0 billion in the fiscal second quarter of 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition.

•Includes a restructuring related charge of $0.1 billion in both the fiscal second quarter of 2021 and 2020, respectively.

•Includes intangible amortization expense of $0.3 billion and $0.2 billion in the fiscal second quarter and $0.5 billion in both the fiscal six months of 2021 and 2020, respectively.

•Includes an unrealized gain on securities of $0.1 billion in both the fiscal second quarter and the fiscal six months of 2021.

(4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas

SALES BY GEOGRAPHIC AREA

						Fiscal Second Quarter Ended																		Fiscal Six Months Ended
(Dollars in Millions)						July 4, 2021						June 28, 2020						Percent Change						July 4, 2021						June 28, 2020						Percent Change
United States						$	11,919					9,539						24.9		%				$	23,030					20,238						13.8		%
Europe						5,668						4,063						39.5						11,082						8,890						24.7
Western Hemisphere, excluding U.S.						1,367						1,133						20.6						2,791						2,635						5.9
Asia-Pacific, Africa						4,358						3,601						21.0						8,730						7,264						20.2
Total						$	23,312					18,336						27.1		%				$	45,633					39,027						16.9		%

X

- Definition

Sales by segment of business.

+ References

No definition available.

+ Details

Name:	jnj_SalesBySegmentOfBusinessTableTextBlock
Namespace Prefix:	jnj_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

Name:	us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration